Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)
To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.
Prostate Cancer
DRUG: rofecoxib|DRUG: Comparator: placebo (unspecified)
Time to prostate cancer, Duration of Treatment
Time to aggressive prostate cancer, Duration of Treatment
The duration of treatment is 6 years.